BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System

Rhea-AI Summary

BD (NYSE:BDX) received a Vizient Innovative Technology contract for its BD CentroVena One™ Insertion System, the first all-in-one central venous catheter insertion system.

The system integrates multiple components to simplify central line placement, with 30% fewer steps and up to 50% lower maximum procedure time in simulation.

AI-generated analysis. Not financial advice.

News Market Reaction – BDX

+2.28%

1 alert

+2.28% News Effect

On the day this news was published, BDX gained 2.28%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Step reduction: 30% fewer steps Procedure time reduction: 50% reduction in maximum procedure time Simulation sample size: 49 procedures (N = 49) +2 more

5 metrics

Step reduction 30% fewer steps CentroVena One vs traditional central line insertion in simulation

Procedure time reduction 50% reduction in maximum procedure time CentroVena One vs standard techniques in simulation

Simulation sample size 49 procedures (N = 49) Head-to-head simulation study in The Journal of Emergency Medicine

Study publication date December 2025 Publication date of head-to-head simulation study

Vizient purchasing volume $156 billion annual purchasing volume Vizient portfolio purchasing volume referenced in article

Peers on Argus

BDX traded lower while peers showed mixed, mostly modest moves with both decline...

BDX traded lower while peers showed mixed, mostly modest moves with both declines and small gains, suggesting today's action is more stock-specific than a broad sector rotation.

Historical Context

5 past events · Latest: May 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
May 21	Product launch	Positive	-0.5%	Launch of Elyra thulium fiber laser for kidney stone procedures.
May 18	Leadership change	Positive	-0.8%	Appointment of Peter Menziuso as EVP and president of BD Interventional.
May 07	CFO appointment	Positive	+5.9%	Vitor Roque named permanent CFO after serving in interim role.
May 07	Earnings results	Positive	+5.9%	Q2 FY2026 beat with guidance raise and capital return actions.
May 05	Strategic partnership	Positive	-1.5%	AI-powered medication management collaboration with Wellstar Health System.

Pattern Detected

BDX has reacted strongly to major financial/leadership updates, while product and partnership news have often seen modest or negative next-day moves.

Regulatory & Risk Context

Short Interest: 2.61%

Short Interest

2.61% of shares outstanding

as of 2026-05-29 Days to cover: 2.41

Short interest appears relatively low, suggesting limited squeeze risk but not eliminating the potential for normal volatility around news and broader market moves.

Market Pulse Summary

This announcement highlights Vizient’s Innovative Technology contract for CentroVena One, citing 30%...

Analysis

This announcement highlights Vizient’s Innovative Technology contract for CentroVena One, citing 30% fewer steps and a 50% cut in maximum procedure time. Recent net insider selling and execution on broader product launches remain key watchpoints.

Key Terms

central venous catheter, guidewire, embolism, needlestick injury

4 terms

central venous catheter medical

"The CentroVena One™ Insertion System is the first and only all-in-one central venous catheter insertion system"

A central venous catheter is a thin, flexible tube placed into a large vein near the neck, chest, or groin to deliver medications, fluids, nutrition, or to measure pressures inside the body. For investors it matters because demand, safety, infection risk, and regulatory changes around these devices and the procedures to place them can affect hospital spending, device makers’ sales, and liability or reimbursement trends—think of it as a dedicated shipping lane for critical medical treatments.

guidewire medical

"By integrating the guidewire, needle, syringe and catheter into a single system"

A guidewire is a thin, flexible metal wire used by doctors to steer catheters and other tools through blood vessels or body passages during minimally invasive medical procedures. For investors, guidewires matter because they are essential, often single-use components whose sales track procedure volume, hospital buying patterns, regulatory approvals, patent protection and liability exposure—similar to a small but critical part in a machine that drives steady, repeatable revenue for device makers.

embolism medical

"may reduce contamination risk and protect against complications such as air and guidewire embolism"

An embolism is a sudden blockage of a blood vessel caused by material—such as a blood clot, air bubble, fat, or other debris—that travels through the bloodstream and lodges in an artery, cutting off blood flow to an organ. It matters to investors because embolisms drive demand for medical treatments, influence safety profiles and regulatory approvals for drugs and devices, and can affect healthcare costs, liability and market confidence; think of it like a traveling cork that suddenly clogs a supply pipe and causes damage downstream.

needlestick injury medical

"protect against complications such as air and guidewire embolism, needlestick injury and clinician blood exposure"

A needlestick injury occurs when a used needle or other sharp medical device accidentally punctures a person’s skin, potentially exposing them to bloodborne infections or hazardous drugs. Investors should care because such injuries create direct medical and legal costs, can trigger regulatory scrutiny and workplace-safety investigations, and may damage reputation and operational continuity in healthcare or manufacturing settings—similar to a workplace accident that can halt production and raise liability expenses.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Recognition from Vizient validates CentroVena One™ as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safety

FRANKLIN LAKES, N.J., June 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD® CentroVena One™ Insertion System has been awarded an Innovative Technology contract from Vizient®, the nation's largest provider-driven healthcare performance improvement company. This contract recognizes products with the potential to drive meaningful improvements in healthcare delivery.

The contract was awarded following a review by hospital experts serving on Vizient's client-led councils, and recognizes that CentroVena One™ offers differentiated capabilities through its all-in-one design with the potential to enhance clinical care, improve patient and clinician safety and streamline procedural workflows.

"Receiving a Vizient Innovative Technology contract recognizes the innovation behind CentroVena One™ and its potential to redefine how central lines are placed," said Eric Borin, worldwide president, Medication Delivery Solutions at BD. "It validates the clear clinical need we are hearing from customers for a simpler, more standardized approach to central line insertion, helping clinicians work more efficiently while supporting safer patient care. We're excited to bring this innovation to more Vizient clients, clinicians and the patients they serve."

Traditional central line insertion may involve dozens of steps and multiple component exchanges, creating potential opportunities for error, contamination and delay. The CentroVena One™ Insertion System is the first and only all-in-one central venous catheter insertion system designed to simplify central line placement and enhance patient safety. By integrating the guidewire, needle, syringe and catheter into a single system, it streamlines workflow and reduces procedural complexity with 30% fewer steps and a 50% reduction in maximum procedure time^* compared to standard techniques.

The system also incorporates safety-focused design elements which may reduce contamination risk and protect against complications such as air and guidewire embolism, needlestick injury and clinician blood exposure. CentroVena One™ is designed to bring greater consistency to the procedure and support more efficient workflows.

"Through the Vizient client-led council evaluation process, CentroVena One™ Insertion System demonstrated the potential to offer meaningful differentiation in today's competitive landscape. After careful review, the council recommended an Innovative Technology contract to BD," said Kelly Flaharty, associate vice president, contract operations for Vizient.

Vizient represents a diverse client base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers and has a portfolio that represents more than $156 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with client-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare. If it is determined that a product is innovative, Vizient may award a contract outside of the competitive bid cycle.

^*Compared to a traditional CVC in a head-to-head simulation study (N = 49) published in The Journal of Emergency Medicine (December 2025). Results may not reflect actual clinical performance.

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at  www.linkedin.com/company/bd1/, X  @BDandCo or Instagram @becton_dickinson.

Contacts:
Media	Investors
Matt Marcus VP, Public Relations Matt.Marcus@bd.com	Shawn Bevec SVP, Investor Relations Investor_Relations@bd.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-awarded-vizient-innovative-technology-contract-for-centrovena-one-insertion-system-302806802.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

What did BD (NYSE:BDX) announce about the CentroVena One insertion system on June 23, 2026?

BD announced that its CentroVena One™ Insertion System received a Vizient Innovative Technology contract. According to BD, the recognition follows a client-led council review highlighting the product’s differentiated, all-in-one design and its potential to improve central line insertion workflows and safety.

What is the BD CentroVena One™ Insertion System and how does it work?

CentroVena One™ is an all-in-one central venous catheter insertion system that integrates guidewire, needle, syringe and catheter. According to BD, this design standardizes central line placement, streamlines workflow and supports patient and clinician safety during central line insertion procedures.

How does CentroVena One™ compare to traditional central line insertion techniques?

CentroVena One™ is reported to reduce procedural steps and maximum procedure time versus standard methods. According to BD, it delivers 30% fewer steps and a 50% reduction in maximum procedure time in a head-to-head simulation study, potentially simplifying central line placement.

What safety features are included in BD’s CentroVena One™ Insertion System?

CentroVena One™ incorporates safety-focused elements intended to reduce contamination and complication risks. According to BD, the system aims to help protect against air and guidewire embolism, needlestick injuries and clinician blood exposure, while bringing greater consistency to central line insertion procedures.

Why is the Vizient Innovative Technology contract important for BD’s CentroVena One™ (BDX)?

The Vizient Innovative Technology contract signals that hospital experts see meaningful differentiation in CentroVena One™. According to BD, the contract may help broaden access to Vizient’s large, diverse client base, potentially accelerating adoption of the system in central line insertion practices.